ERBB2 and breast carcinoma: Although breast tumour resection may lead to a high survival rate for breast cancer patients diagnosed at early stages, locally advanced and highly invasive and metastatic breast cancer subtypes are generally refractory to current anti-hormonal treatments, targeted therapies against erbB2/HER2, irradiation and chemotherapies [160, 237, 238].